SEARCH

SEARCH BY CITATION

References

  • 1
    Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263283.
  • 2
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227242.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661662.
  • 4
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 13091319.
  • 5
    Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628638.
  • 6
    Chen CF, Lee WC, Yang HI et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 12401248.
  • 7
    Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886893.
  • 8
    Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 9
    Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 10111020.
  • 10
    Chang TT, Lai CL, Kew YS et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422430.
  • 11
    Shouval D, Lai CL, Chang TT et al. Three years of entecavir re-treatment of HBeAg(−) entecavir patients who previously discontinued entecavir therapy: results from study ETV-901. Hepatology 2008; 48(Suppl. 1): 722A723A.
  • 12
    Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 14371444.
  • 13
    Manns M, Akarca US, Chang TT et al. Low rates of nucleos(t)ide-associated adverse events in the long-term experience with entecavir. J Hepatol 2010; 52: S393.
  • 14
    Tenney DJ, Pokornoski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naïve patients. J Hepatol 2009; 50(Suppl 1): S10.
  • 15
    Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49(5): 15031514.
  • 16
    Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359(23): 24422455.
  • 17
    Heathcote EJ, Gane EJ, de Man RA et al. Long-term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients with chronic hepatitis B (study 103). Hepatology 2010; 52(Suppl 1): Abstract 477.
  • 18
    Marcellin P, Buti M, Krastev Z et al. Continued efficacy and safety through 4 years of tenofovir disproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (study 102). Hepatology 2010; 52(Suppl 1): Abstract 476.
  • 19
    Snow-Lampart A, Chappell B, Curtis M et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763773.
  • 20
    Snow-Lampart A, Kitrinos K, Chappell B et al. No resistance to tenofovir disoproxil fumarate (TDF) detected following up to 192 weeks of treatment in subjects monoinfected with chronic hepatitis B virus. Hepatology 2010; 52(Suppl 1): Abstract 1365.
  • 21
    Marcellin P, Buti M, Gane EJ et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011; 54(Suppl 1): Abstract 1375.
  • 22
    Buti M, Morillas RM, Prieto M et al. A viral load reduction >3 log at 12 week of Entecavir treatment correlated with HBe seroconversion in HBeag positive patients. Results from a real-life setting study (the ORIENTE study). Hepatology 2010; 52(Suppl 1): Abstract 409.
  • 23
    Zoutendijk R, Reijnders JG, Brown A et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443451.
  • 24
    Zoutendik R, Rejinders GP, Zoulim F et al. Virological response to entecavir is associated with a lower probability of disease progression in chronic hepatitis B. Hepatology 2011; 54(Suppl 1): Abstract 240.
  • 25
    Ridruejo E, Adrovar R, Cocozella D et al. Effectiveness of entecavir in chronic hepatitis B NUC-naïve patients in routine clinical practice. Int J Clin Pract 2011; 65: 866870.
  • 26
    Carey I, Nguyen H-L, Joe D et al. De-novo antiviral therapy with nucleos(t)ide analogues in ‘real-life’ pateints with chronic hepatitis B infection: comparison of virological responses between lamivudine+adefovir, entecavir vs. tenofovir therapy. Hepatology 2011; 54(Suppl 1): Abstract 1396.
  • 27
    Lampertico P, Vigano M, Soffredini R et al. Entecavir monotherapy for nuc-naive chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 years. Hepatology 2011; 54(Suppl 1): Abstract 1436.
  • 28
    Seto WK, Lai CL, Fung J, Yuen JC, Wong DK, Yuen MF. Outcome of 4-year treatment of entecavir for treatment-naïve chronic hepatitis B. J Hepatol 2011; 54: S301.
  • 29
    Lampertico P, Soffredini R, Vigano M et al. 2 year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology 2011; 54(Suppl 1): Abstract 1433.
  • 30
    Mazzucco CE, Hamatake RK, Colonno RJ, Tenney DJ. Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition. Antimicrob Agents Chemother 2008; 52: 598605.
  • 31
    Lange CM, Bojunga J, Hofmann WP et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 20012006.
  • 32
    Lange CM, Sprinzl K, Vermerhren J, Zeuzem S, Sarrazin C. Prospektive Untersuchung von Laktat-Konzentrationen im Blut von Patienten mit chronischer Hepatitis B und dekompensierter Leberzirrhose während der Therapie mit Nukleos(t)id-Analoga. Med Klin 2010; 1(14): PS25.
  • 33
    Shim JH, Lee HC, Kim KM et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176182.
  • 34
    Liaw YF, Sheen IS, Lee CM et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 6272.
  • 35
    Liaw YF, Raptopoulou-Gigi M, Cheinquer H et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2011; 54: 91100.
  • 36
    Duarte-Rojo A, Heathcote J. Efficacy and safety of tenofovir disoproxil fumerate in patients with chronic hepatitis B. Therap Adv Gastroenterol 2010; 3: 107119.
  • 37
    Mauss S, Berger F, Filmann N et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: 12351240.
  • 38
    European medicines agency. Summary of Product Characteristics. August 2011. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000419/human_med_001144.jsp?murl=menus/medicines/medicines.jsp?jsenabled=true Accessed 28 September 2011.
  • 39
    Ha NB, Ha NB, Garcia RT et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011; 56: 24232431.
  • 40
    Sogni P, Carrieri MP, Fontaine H et al. The role of adherence in virological suppression in patients receiving anti-HBV analogues: implications for clinical management. Antivir Ther 2012; 17(2): 395400
  • 41
    Brodzinski A, Fueloep B, Schlosser B et al. Prevalence of renal alterations indicative for proximal tubular damage (PTD) in patients with chronic hepatitis B virus infection during long-term treatment with tenofovir disoproxil fumarate (TDF). Hepatology 2010; 52(Suppl 4): Abstract 393.
  • 42
    Lampertico P, Vigano M, Yurdaydin C et al. Effectiveness and safety of tenofovir disproxil fumarate in field practice: a multicentre European cohort study of 737 patients with chronic hepatitis B. Hepatology 2010; 52(Suppl 1): Abstract 369.